Nasdaq:US$40.98 (-0.83) | HKEX:HK$72.05 (-5.55) | AIM:£5.92 (+0.14)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 22 Aug 2014

Discovery of [savolitinib] as a Highly Potent and Selective Mesenchymal-Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer (Journal of Medicinal Chemistry 2014)

For detailed information, please visit:

http://pubs.acs.org/doi/abs/10.1021/jm500510f